Suppr超能文献

1例伴有派杰样播散和导管内癌的前列腺印戒细胞样癌及长期生存:PD-L1和错配修复系统蛋白(MMR)免疫组化评估及系统文献综述

A Case of Prostatic Signet-Ring Cell-like Carcinoma with Pagetoid Spread and Intraductal Carcinoma and Long-Term Survival: PD-L1 and Mismatch Repair System Proteins (MMR) Immunohistochemical Evaluation with Systematic Literature Review.

作者信息

Koufopoulos Nektarios, Ieronimaki Argyro-Ioanna, Zacharatou Andriani, Gouloumis Alina Roxana, Leventakou Danai, Boutas Ioannis, Dimas Dionysios T, Kontogeorgi Adamantia, Sitara Kyparissia, Khaldi Lubna, Zanelli Magda, Palicelli Andrea

机构信息

Second Department of Pathology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 15772 Athens, Greece.

Breast Unit, Rea Maternity Hospital, P. Faliro, 17564 Athens, Greece.

出版信息

J Pers Med. 2023 Jun 19;13(6):1016. doi: 10.3390/jpm13061016.

Abstract

Prostatic adenocarcinoma (PA) is the second most common malignancy in men globally. Signet-ring cell-like adenocarcinoma (SRCC) is a very rare PA subtype, with around 200 cases reported in the English literature. Histologically, the tumor cells show a vacuole compressing the nucleus to the periphery. Pagetoid spread in acini and ducts is usually related to metastases from urothelial or colorectal carcinomas, less commonly associated with intraductal carcinoma (IC); histologically, the tumor cells grow between the acinar secretory and basal cell layers. To our knowledge, we report the first prostatic SRCC (Gleason score 10, stage pT3b) associated with IC and pagetoid spread to prostatic acini and seminal vesicles. To our systematic literature review (PRISMA guidelines), it is the first tested case for both PD-L1 (<1% of positive tumor cells, clone 22C3) and mismatch repair system proteins (MMR) (MLH1+/MSH2+/PMS2+/MSH6+). We found no SRCC previously tested for MMR, while only four previous cases showed high expression of another PD-L1 clone (28-8). Finally, we discussed the differential diagnoses of prostatic SRCC.

摘要

前列腺腺癌(PA)是全球男性中第二常见的恶性肿瘤。印戒样细胞腺癌(SRCC)是一种非常罕见的PA亚型,英文文献中报道了约200例病例。在组织学上,肿瘤细胞呈现一个将细胞核挤压至周边的空泡。腺泡和导管中的派杰样播散通常与尿路上皮癌或结直肠癌的转移有关,较少与导管内癌(IC)相关;在组织学上,肿瘤细胞在腺泡分泌层和基底细胞层之间生长。据我们所知,我们报告了首例与IC以及派杰样播散至前列腺腺泡和精囊相关的前列腺SRCC( Gleason评分10分,pT3b期)。根据我们的系统文献综述(PRISMA指南),这是首例同时检测程序性死亡受体1配体(PD-L1)(阳性肿瘤细胞<1%,克隆号22C3)和错配修复系统蛋白(MMR)(MLH1+/MSH2+/PMS2+/MSH6+)的病例。我们未发现之前有针对MMR检测的SRCC病例,而之前仅有4例病例显示另一种PD-L1克隆(28-8)高表达。最后,我们讨论了前列腺SRCC的鉴别诊断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/10303679/0f1a9a4116d8/jpm-13-01016-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验